Canadian Treatments for COVID-19 (CATCO)

CATCO - A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients. The study is conducted in conjunction with the Public health emergency SOLIDARITY TRIAL PLUS (World Health Organization (WHO)). WHO is the Global sponsor. CATCO is funded by CIHR.

Given the adoptive nature of this trial, updated information about the trail can be found at ClinicalTrials.gov or on the Sunnybrook COVID-19 Research Webpage.

Below are some links to publications from the study data:

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

Remdesivir in Patients with Severe Kidney Dysfunction

Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19

WHO SOLIDARITY Publications, which included CATCO Data:

Repurposed Antiviral Drugs for COVID-19 – Interim WHO SOLIDARITY Trial Results

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses